During the month of April financial markets partially recovered from the most volatile month on record and one of the swiftest and most severe re-pricing of risk assets experienced during the year’s first quarter.
On May 11, 2020 the first ever randomized study in obstructive, hypertrophic cardiomyopathy had decisively positive results. The news had a clinical-stage biotech company’s shares up considerably. This is the second major win for industry in developing precision cardiology medicines.
Featured Commentary
Driehaus Event Driven April 2020 Commentary and Attribution
By Alternative Investments
During the month of April financial markets partially recovered from the most volatile month on record and one of the swiftest and most severe re-pricing of risk assets experienced during the year’s first quarter.
An Example in Precision Medicine in Cardiology
By Michael Caldwell
On May 11, 2020 the first ever randomized study in obstructive, hypertrophic cardiomyopathy had decisively positive results. The news had a clinical-stage biotech company’s shares up considerably. This is the second major win for industry in developing precision cardiology medicines.